Intézmény

D’Or Institute for Research and Education

Rio de Janeiro, BrazíliaHonlap

Más néven: Instituto D’Or de Pesquisa e Ensino · IDOR

19futó vizsgálat
8lezárt vizsgálat
3407publikáció (OpenAlex)

Futó vizsgálatok

Toboroz
A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Lower Risk Myelodysplastic Syndromes (LR-MDS) Who Need Regular Blood Transfusions
NCT07422480· 3. fázis· Takeda· Forrás
Toboroz
A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma
NCT06980480· 3. fázis· Takeda· Forrás
Toboroz
A Study to Assess Zipalertinib Versus Placebo in Participants With Early Stage NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection
NCT07128199· 3. fázis· Taiho Oncology, Inc.· Forrás
Toboroz
TIL-Driven De-escalated Chemotherapy in Stage I-II TNBC
NCT07074106· 2. fázis· D'Or Institute for Research and Education· Forrás
Toboroz
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
NCT07213804· 3. fázis· Eli Lilly and Company· Forrás
Toboroz
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
NCT06758401· 3. fázis· Pfizer· Forrás
Toboroz
A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart
NCT06935370· 3. fázis· Boehringer Ingelheim· Forrás
Toboroz
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
NCT06890598· 3. fázis· Eli Lilly and Company· Forrás
Meghívásos bevonás
Development of Polygenic Risk Scores in Colon Cancer Patients Through the Study of Ancestry and Diversity in Genetic Maps of the Brazilian Population - ORIGEM Project
NCT06917794· D'Or Institute for Research and Education· Forrás
Fut, nem toboroz
Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06)
NCT06635824· 3. fázis· Genmab· Forrás
Toboroz
A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.
NCT06629779· 3. fázis· Pfizer· Forrás
Fut, nem toboroz
Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy (ASCENT-GYN-01/GOG-3104/ENGOT-en26)
NCT06486441· 3. fázis· Gilead Sciences· Forrás
Fut, nem toboroz
Agnostic Therapy in Rare Solid Tumors
NCT06638931· 2. fázis· Instituto do Cancer do Estado de São Paulo· Forrás
Toboroz
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
NCT06119581· 3. fázis· Eli Lilly and Company· Forrás
Fut, nem toboroz
A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)
NCT06065748· 3. fázis· Hoffmann-La Roche· Forrás
Fut, nem toboroz
A Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy in Local Advanced or Metastatic Non-small Cell Lung Cancer (WU-KONG28)
NCT05668988· 3. fázis· Dizal Pharmaceuticals· Forrás
Fut, nem toboroz
A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.
NCT04224493· 3. fázis· Epizyme, Inc.· Forrás
Fut, nem toboroz
Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPC
NCT03395197· 3. fázis· Pfizer· Forrás
Fut, nem toboroz
A Study for Cardiovascular and Lifestyle Risk Factors in Prostate Cancer Patients
NCT03127631· McMaster University· Forrás

Egyszerre toboroz

Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.

Vastagbélrák7 toboroz
Tüdőrák4 toboroz
Mielodiszplasztikus szindróma (MDS)1 toboroz
Mielóma multiplex1 toboroz
Petefészekrák1 toboroz
Prosztatarák1 toboroz
Szívelégtelenség1 toboroz
Tripla negatív emlőrák1 toboroz

Lezárt vizsgálatok

Visszavonták
A Study in Adults With Advanced Classical Hodgkin's Lymphoma (cHL) in Brazil Treated With Brentuximab Vedotin Together With Chemotherapy Compared to Chemotherapy Alone
NCT06104878· Takeda· Forrás
Lezárult
Levels of Inflammation in People With Cardiovascular Disease (POSEIDON)
NCT06122961· Novo Nordisk A/S· Forrás
Lezárult
A Study of JNJ-77242113 in Participants With Moderately to Severely Active Ulcerative Colitis
NCT06049017· 2. fázis· Janssen Research & Development, LLC· Forrás
Leállították
A Study of LY3540378 in Participants With Worsening Chronic Heart Failure With Preserved Ejection Fraction (HFpEF)
NCT05592275· 2. fázis· Eli Lilly and Company· Forrás
Lezárult
Impact of CardiolRx on Myocardial Recovery in Patients With Acute Myocarditis
NCT05180240· 2. fázis· Cardiol Therapeutics Inc.· Forrás
Lezárult
Tolerance to Immunomodulatory Nutritional Therapy in Oncology Patients Undergoing Chemotherapy and Radiotherapy
NCT07021378· D'Or Institute for Research and Education· Forrás
Lezárult
Effect of Tumor Treating Fields (TTFields, 150 kHz) as Front-Line Treatment of Locally-advanced Pancreatic Adenocarcinoma Concomitant With Gemcitabine and Nab-paclitaxel (PANOVA-3)
NCT03377491· 3. fázis· NovoCure Ltd.· Forrás
Lezárult
Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome
NCT03473223· 3. fázis· CSL Behring· Forrás

Regiszterbeli névváltozatok (14)

A vizsgálati regiszterek ezeken a neveken tartják nyilván az intézményt. Minden sor egy regiszterbejegyzés: a címe és az alatta nyilvántartott vizsgálatok.

Instituto D'Or de Pesquisa e Ensino
Rio de Janeiro, 22031-011
8 vizsgálat
Instituto D'or de Pesquisa e Ensino
São Paulo, São Paulo 04.501-000
6 vizsgálat
Instituto D'Or Pesquisa e Ensino
Rio de Janeiro, 22271-110
5 vizsgálat
Instituto D'Or de Pesquisa e Ensino
Brasília, Federal District 70390-140
2 vizsgálat
- NCT06917794Development of Polygenic Risk Scores in Colon Cancer Patients Through the Study of Ancestry and Diversity in Genetic Maps of the Brazilian Population - ORIGEM Project
- NCT06104878A Study in Adults With Advanced Classical Hodgkin's Lymphoma (cHL) in Brazil Treated With Brentuximab Vedotin Together With Chemotherapy Compared to Chemotherapy Alone
Instituto D'Or de Pesquisa e Ensino
Fortaleza, Ceará 60135-237
2 vizsgálat
- NCT06917794Development of Polygenic Risk Scores in Colon Cancer Patients Through the Study of Ancestry and Diversity in Genetic Maps of the Brazilian Population - ORIGEM Project
- NCT06629779A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.
Instituto D'Or de Pesquisa e Ensino
Recife, 52010-010
2 vizsgálat
- NCT06917794Development of Polygenic Risk Scores in Colon Cancer Patients Through the Study of Ancestry and Diversity in Genetic Maps of the Brazilian Population - ORIGEM Project
- NCT05668988A Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy in Local Advanced or Metastatic Non-small Cell Lung Cancer (WU-KONG28)
Instituto D'Or de Pesquisa e Ensino
Salvador, Estado de Bahia 40414-120
2 vizsgálat
- NCT06980480A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma
  Contact: Edvan Crusoe (principal investigator)
- NCT06917794Development of Polygenic Risk Scores in Colon Cancer Patients Through the Study of Ancestry and Diversity in Genetic Maps of the Brazilian Population - ORIGEM Project
Instituto D'Or Pesquisa e Ensino - Rio de Janeiro
Rio de Janeiro, Rio Do Janeiro 22281-100
2 vizsgálat
- NCT06935370A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart
  Contact: Boehringer Ingelheim
- NCT06635824Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06)
0760075 - Instituto D'Or de Pesquisa e Ensino
Rio de Janeiro, 22281-100
1 vizsgálat
- NCT03473223Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome
D'OR Institute for Research and Education
Salvador, Estado de Bahia 41253-190
1 vizsgálat
- NCT07422480A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Lower Risk Myelodysplastic Syndromes (LR-MDS) Who Need Regular Blood Transfusions
  Contact: Laine Santos Fiscina Alvarenga (principal investigator)
Instituto D'Or de Pesquisa e Ensino
Curitiba, Paraná 80420-090
1 vizsgálat
- NCT06917794Development of Polygenic Risk Scores in Colon Cancer Patients Through the Study of Ancestry and Diversity in Genetic Maps of the Brazilian Population - ORIGEM Project
Instituto D'Or de Pesquisa e Ensino do Rio de Janeiro
Rio de Janeiro
1 vizsgálat
- NCT07074106TIL-Driven De-escalated Chemotherapy in Stage I-II TNBC
  Contact: Intituto D'Or de Pesquisa e Ensino São Paulo
Instituto D'Or de Pesquisa e Ensino - Rio de Janeiro
Botafogo, Rio de Janeiro 22281-100
1 vizsgálat
- NCT07128199A Study to Assess Zipalertinib Versus Placebo in Participants With Early Stage NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection
  Contact: Taiho Oncology, Inc.
Instituto D'Or de Pesquisa e Ensino - Rio De Janeiro
Rio de Janeiro, 22271
1 vizsgálat
- NCT03377491Effect of Tumor Treating Fields (TTFields, 150 kHz) as Front-Line Treatment of Locally-advanced Pancreatic Adenocarcinoma Concomitant With Gemcitabine and Nab-paclitaxel (PANOVA-3)

Betegségek

Betegségek, amelyekről az intézmény publikál vagy amelyekre vizsgálatot futtat.

Tripla negatív emlőrák23 munka · 1 vizsgálat
Follikuláris limfóma11 munka · 1 vizsgálat

Intézményadatok: ROR 01mar7r17 (CC0-1.0)Frissítve: 2026. nov. 10.

Hibát jelzek